title: Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
abstract: OBJECTIVE
  Clinical studies evaluating the role of leptin and adiponectin on bone metabolism had shown conflicting results, and data about the effect of anticatabolic drugs on these adipokines are scarce. Our aims were to determine adiponectin and leptin levels in osteoporotic postmenopausal women and their relationship with bone mass and bone turnover and to analyze changes on adiponectin and leptin levels after treatment with raloxifene or alendronate.
  
  
  METHODS
  We selected 53 women (mean ± SD age, 63 ± 7 y) with postmenopausal osteoporosis divided into two treatment groups: raloxifene (60 mg/d; n = 20) or alendronate (70 mg/wk; n = 33) during a period of 1 year. Bone mineral density by dual-energy x-ray absorptiometry and serum levels of leptin, adiponectin, and bone turnovers markers were determined at baseline and at 1 year after treatment.
  
  
  RESULTS
  Baseline levels of leptin were correlated to body mass index (r = 0.47; P < 0.01), waist circumference (r = 0.38, P = 0.01), and estradiol (r = 0.4, P = 0.003). Adiponectin was inversely related to bone-specific alkaline phosphatase (r = -0.41, P < 0.01) and serum crosslaps (r = -0.35; P < 0.01). There was no correlation between bone mineral density, leptin, and adiponectin. After 12 months, no changes were observed in leptin and adiponectin in the alendronate group; however, a significant increase in leptin levels (973.5 ± 637.4 pM/mL vs 1,305.7 ± 793.5 pM/mL; P = 0.031) was detected in the raloxifene group, whereas adiponectin levels showed no significant changes (P = 0.46).
  
  
  CONCLUSIONS
  In postmenopausal women with osteoporosis, raloxifene induces a significant increase in leptin levels without significant changes in adiponectin serum levels. The antiresorptive effect of raloxifene and alendronate is not substantially influenced by changes in leptin or adiponectin levels.
authors.affiliation: Endocrinology Division, Hospital Universitario San Cecilio, Granada, Spain.
authors.forename: Arántzazu
authors.initials: A
authors.lastname: Sebastián-Ochoa
authors.forename: Diego
authors.initials: D
authors.lastname: Fernández-García
authors.forename: Rebeca
authors.initials: R
authors.lastname: Reyes-García
authors.forename: Pedro
authors.initials: P
authors.lastname: Mezquita-Raya
authors.forename: Pedro
authors.initials: P
authors.lastname: Rozas-Moreno
authors.forename: Guillermo
authors.initials: G
authors.lastname: Alonso-Garcia
authors.forename: Manuel
authors.initials: M
authors.lastname: Muñoz-Torres
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D019386:Alendronate / Q000494:pharmacology / Q000627:therapeutic use*; D015992:Body Mass Index; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D020738:Leptin / Q000097:blood*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D052242:Adiponectin; D050071:Bone Density Conservation Agents; D020738:Leptin; D020849:Raloxifene Hydrochloride; D019386:Alendronate